Abstract:PurposeThe primary aim of this study was to closely monitor and identify adverse events (AEs) linked to lenvatinib, a pharmacotherapeutic agent employed for the management of renal cell carcinoma, thyroid cancer, and hepatocellular carcinoma. The ultimate goal was to optimize patient safety and provide evidence-based guidance for the appropriate utilization of this medication.MethodsA comprehensive collection and analysis of reports from the FDA Adverse Event Reporting System (FAERS) database was conducted, encompassing the period from the first quarter of 2015 to the first quarter of 2023. Disproportionality analysis, employing robust algorithms including ROR, PRR, BCPNN, and EBGM was employed for effective data mining to quantify signals associated with lenvatinib-related AEs.ResultsAmong the collected reports, a total of 15,193 cases were identified where lenvatinib was the “primary suspected (PS)" drug, resulting in 50,508 lenvatinib-induced AEs. An analysis was conducted to examine the occurrence of lenvatinib-induced adverse drug reactions (ADRs) across 26 organ systems. The findings revealed the presence of expected ADRs, including diarrhea, vomiting, stomatitis, hepatic encephalopathy, decreased appetite, dehydration, decreased weight, and electrolyte imbalances, which were consistent with the information provided in the drug labels. Furthermore, unexpected significant ADRs were observed at the preferred terms (PT) level, such as interstitial lung disease, pneumothorax, hypophysitis, failure to thrive, polycythemia, hypopituitarism, spontaneous pneumothorax, pulmonary cavitation, and limbic encephalitis. These findings indicated the potential occurrence of adverse effects that are currently not documented in the drug instructions.ConclusionsThis study has successfully detected novel and unforeseen signals pertaining to ADRs associated with the administration of lenvatinib, thereby contributing significant insights into the intricate correlation between ADRs and the utilization of lenvatinib. The outcomes of this investigation underscore the utmost significance of continuous monitoring and vigilant surveillance in order to promptly identify and effectively manage AEs, consequently enhancing overall patient safety and well-being in the context of lenvatinib therapy.

Safety assessment of cabozantinib in patients with renal cell carcinoma: retrospective pharmacovigilance study based on FAERS database

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system

A real-world drug safety surveillance study of lenvatinib from the FAERS database

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) for gemcitabine

Adverse Events of Cabozantinib as a Potential Prognostic Factor in Metastatic Renal Cell Carcinoma Patients: Real-World Experience in a Single-Center Retrospective Study

Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis

A real-world pharmacovigilance study of tafasitamab: data mining of the US food and drug administration adverse event reporting system

Adverse events with pemigatinib in the real world: a pharmacovigilance study based on the FDA Adverse Event Reporting System

Assessment of adverse events of the novel cardiovascular drug vericiguat: a real-world pharmacovigilance study based on FAERS

Safety study on adverse events of zanubrutinib based on WHO-VigiAccess and FAERS databases

Risk analysis of enfortumab vedotin: A real-world approach based on the FAERS database

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib

Novel Insights into Post-Marketing Adverse Events Associated with Lenvatinib: A Comprehensive Analysis Utilizing the FAERS Database

Evaluate the Renal System Damage Caused by Zoledronic Acid: A Comprehensive Analysis of Adverse Events from FAERS

Early Presence of Antiangiogenesis-Related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Patients with Metastatic Gastric Cancer Treated with Apatinib.

Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database

Real-world pharmacovigilance study of FDA adverse event reporting system events for finerenone

Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project

A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System Events for Trametinib

A real-world disproportionality analysis of Tivozanib data mining of the public version of FDA adverse event reporting system

A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system